• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

firstwordpharmaJune 23, 2021

Tag: Novartis , BioNTech , COVID-19 , Vaccine

Novartis aims to bottle more than 50 million doses of BioNTech’s COVID-19 vaccine this year at its fill-and-finish facility in Stein, Switzerland, as reported in KFGO.

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

The news comes after the European Union’s drug regulator approved the bottling plant.


Previous:Cyteir Therapeutics Announces Closing of Initial Public Offering

Next:Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021 | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect
Group ACYW135 Meningococcal Polysaccharide Vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine

High-standard and safety Influenza Vaccine (Split virion), inactivated

High-standard and safety Influenza Vaccine (Split virion), inactivated
trivalent flu vaccine

trivalent flu vaccine
Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological
Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality
Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard and Produce

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard and Produce
Meningococcal Polysaccharide Vaccine Group ACYW135

Meningococcal Polysaccharide Vaccine Group ACYW135
Quadrivalent Influenza Vaccine HUALAN

Quadrivalent Influenza Vaccine HUALAN
2024-2025 flu vaccine

2024-2025 flu vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service